# Therini Bio, Inc.: Research, Sacramento, United States

> Therini Bio, Inc.: Therini Bio, Inc. is a clinical-stage biotechnology company focused on developing fibrin-targeting immunotherapies to address chronic...

Source: https://millionrounds.com/startup/therini-bio-inc (Millionrounds; every figure on the page links to its filing or article)

United States · [Research startup](https://millionrounds.com/companies)

# Therini Bio, Inc.

Therini Bio, Inc. is a clinical-stage biotechnology company focused on developing fibrin-targeting immunotherapies to address chronic neuroinflammation and neuronal damage associat

Email

Funding reported Last round: Series A

Research Sacramento, United States

Follow Therini Bio, Inc. and see its new rounds in your feed. [Start following](https://millionrounds.com/login?join=1&why=follow&next=%2Fstartup%2Ftherini-bio-inc)

Company summary

- **Founded:** 2016 10 years old
- **Team:** 15 11 to 50 people
- **Funding reported:** $65M in dollars
- **Last round:** Series A Apr 2023

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for Therini Bio, Inc. has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About Therini Bio, Inc.

Therini Bio, Inc. is a clinical-stage biotechnology company focused on developing fibrin-targeting immunotherapies to address chronic neuroinflammation and neuronal damage associat

ed with severe neurological and retinal diseases, including Alzheimer’s Disease and Diabetic Macular Edema (DME). Founded in 2016 and headquartered in South San Francisco, California, Therini Bio is a private company that operates in the Drug Discovery and Biotechnology sectors. The company’s lead product candidate, THN391, is a selective monoclonal antibody designed to block fibrin-driven immune activation without impairing coagulation. Therini Bio's innovative approach targets toxic fibrin deposits, aiming to halt neuroinflammation and protect the nervous system. Their pipeline includes potential first-in-class immunotherapies applicable to a range of inflammatory diseases, with a focus on conditions where neuroinflammation is a key factor. The company has raised over $100 million in funding from notable investors, including Lilly and Sanofi, to support its mission of improving patient outcomes in neurodegenerative and retinal diseases.

## What company datasets say Therini Bio, Inc. raised

Funding, as reported

Reported in all **$65M** in dollars

Rounds **4**

Last round **Series A**

Last round size **$39M**

Last round date **Apr 2023**

Investors listed **9**

## On a portfolio page

Investors who name them

- [Dolby Family Ventures](https://millionrounds.com/fund/dolby-family-ventures)

Each firm lists Therini Bio, Inc. on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

## The company, in detail

What they build

Known for

health care biotechnology research fibrin deposits outside vessels neurodegenerative diseases medical research neurodegenerative retinal diseases neurovascular disease mechanisms monoclonal antibody neurodegeneration retinal diseases alzheimers disease neuroinflammatory diseases hospital & health care pharmacokinetics medical biomarkers

Built with from their website

WordPress.org Apache Viewport Meta Barracuda MSP GlobeNewswire Priority Hints Google Font API Microsoft Exchange FitVids.JS MySQL

+8 more

PrimeNG Microsoft 365 Apps & Services Mobile Friendly Bootstrap Open Graph jQuery RSS Yoast SEO

- **Sector:** Research
- **Industry code:** NAICS 541714, SIC 2834
- **Region:** California
- **Revenue:** $5.0M a year, as listed
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/therini-bio)

## Research in United States

Startups like it

- [**OpenAI** San Francisco · founded 2011 *Raised*](https://millionrounds.com/company/openai)
- [**Retro Biosciences** Redwood City · founded 2021 *Raised*](https://millionrounds.com/company/retro-biosciences)
- [**NewLimit** South San Francisco · founded 2022 *Raised*](https://millionrounds.com/company/newlimit)
- [**Pathos** New York · founded 2022 *Raised*](https://millionrounds.com/company/pathos)
- [**Colossal Biosciences** Dallas · founded 2021 *Raised*](https://millionrounds.com/company/colossal-biosciences)
- [**Oratomic** South Pasadena *Raised*](https://millionrounds.com/company/oratomic)
- [**Beeline Medicines** Stamford · founded 2025 *Raised*](https://millionrounds.com/company/beeline-medicines)
- [**Element Biosciences** San Diego · founded 2017 *Raised*](https://millionrounds.com/company/element-biosciences)

## Is this your company?

Add your raise, your deck and your story, and put Therini Bio, Inc. in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)